Airija - anglų - HPRA (Health Products Regulatory Authority)

cephalon uk limited - amphotericin b - suspension for injection - 5 micromol

Singapūras - anglų - HSA (Health Sciences Authority)

gilead sciences singapore pte. ltd. - amphotericin b - injection, powder, for solution - 50 mg/vial - amphotericin b 50 mg/vial

Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - amphotericin b -

Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cipla malaysia sdn bhd - amphotericin b usp -

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - amphotericin b 100 mg/ml - oral suspension - 100 mg/ml - active: amphotericin b 100 mg/ml excipient: glycerol

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - amphotericin b 50mg (plus 2.5mg overage) - powder for injection - 50 mg - active: amphotericin b 50mg (plus 2.5mg overage) excipient: deoxycholic acid dibasic sodium phosphate dodecahydrate monobasic sodium phosphate dihydrate

Indija - anglų - Central Drugs Standard Control Organization

cipla - amphotericin-b - inj - 50mg(amphotericin en capsulated in liposomes) - 50mg

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fluconazole, quantity: 200 mg - capsule, hard - excipient ingredients: purified water; lactose monohydrate; maize starch; patent blue v; magnesium stearate; titanium dioxide; erythrosine; gelatin; colloidal anhydrous silica; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ozole (fluconazole) capsules, given orally, are indicated for the following conditions: - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the acute phase of cryptococcal meningitis. - maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. - treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. - secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. - serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infecctions. until such data are available, amphotericin b remains the drug of choice. - vaginal candidiasis, when topical therapy has failed. - treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therpy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fluconazole, quantity: 100 mg - capsule, hard - excipient ingredients: titanium dioxide; patent blue v; sodium lauryl sulfate; maize starch; magnesium stearate; lactose monohydrate; colloidal anhydrous silica; erythrosine; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ozole (fluconazole) capsules, given orally, are indicated for the following conditions: - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the acute phase of cryptococcal meningitis. - maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. - treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. - secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. - serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infecctions. until such data are available, amphotericin b remains the drug of choice. - vaginal candidiasis, when topical therapy has failed. - treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therpy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fluconazole, quantity: 50 mg - capsule, hard - excipient ingredients: maize starch; lactose monohydrate; colloidal anhydrous silica; sodium lauryl sulfate; magnesium stearate; patent blue v; purified water; titanium dioxide; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ozole (fluconazole) capsules, given orally, are indicated for the following conditions: - treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the acute phase of cryptococcal meningitis. - maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. - treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. - secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. - serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infecctions. until such data are available, amphotericin b remains the drug of choice. - vaginal candidiasis, when topical therapy has failed. - treatment of extensive tinea corporis, extensive tinea cruris and extensive tinea pedis infections in immunocompetent patients in whom topical therpy is not a practical treatment option. usually, topical therapy should be attempted first because oral therapy has a less favourable ratio of benefits to risks.